Diagnosis, evaluation, and treatment of non-muscle invasive bladder cancer:
Gespeichert in:
| Format: | Buch |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
Philadelphia, Pa.
Elsevier
2013
|
| Schriftenreihe: | Urologic clinics of North America
40,2 |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | XIII S., S. 155 - 321 Ill., graph. Darst. |
| ISBN: | 9781455773459 145577345X |
Internformat
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV041021457 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | t | ||
| 008 | 130517s2013 ad|| |||| 00||| eng d | ||
| 020 | |a 9781455773459 |9 978-1-4557-7345-9 | ||
| 020 | |a 145577345X |9 1-4557-7345-X | ||
| 035 | |a (OCoLC)844112158 | ||
| 035 | |a (DE-599)BVBBV041021457 | ||
| 040 | |a DE-604 |b ger |e rakwb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-19 | ||
| 245 | 1 | 0 | |a Diagnosis, evaluation, and treatment of non-muscle invasive bladder cancer |c ed. Sam S. Chang |
| 264 | 1 | |a Philadelphia, Pa. |b Elsevier |c 2013 | |
| 300 | |a XIII S., S. 155 - 321 |b Ill., graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a Urologic clinics of North America |v 40,2 | |
| 490 | 0 | |a Clinics review articles | |
| 700 | 1 | |a Chang, Sam S. |e Sonstige |4 oth | |
| 830 | 0 | |a Urologic clinics of North America |v 40,2 |w (DE-604)BV000001584 |9 40,2 | |
| 856 | 4 | 2 | |m HBZ Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=025999024&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-025999024 | ||
Datensatz im Suchindex
| _version_ | 1804150330254950400 |
|---|---|
| adam_text | Titel: Diagnosis, evaluation, and treatment of non-muscle invasive bladder cancer
Autor: Chang, Sam S
Jahr: 2013
Diagnosis, Evaluation, and Treatment of Non-Muscle Invasive Bladder Cancer
Contents
Foreword
SamirS.Taneja
XI
Preface: Non-Muscle Invasive Bladder Cancer
XIII
Sam S. Chang
NMIBC Risk Calculators: How Useful Are They for the Practicing Urologist and How Can
RianneJ.M. Lammers, Richard J. Sylvester, Cheryl T. Lee, and J. Alfred Witjes
The natural history of non-muscle invasive bladder cancer (NMIBC) in individual
patients can be unpredictable. Although there are known clinical and molecular fac-
tors associated with tumor recurrence and progression, it is challenging to reconcile
these data during a typical patient encounter within a busy clinic. The authors dis-
cuss the European Organization for Research and Treatment of Cancer s risk tables
along with other models for predicting prognosis in patients with NMIBC. The
authors also describe their advantages and disadvantages and the barriers to using
these risk models in daily clinical practice and provide a future perspective on prog-
nostic models.
Urinary Markers/Cytology: What and When Should a Urologist Use 165
Jeffrey M. Tomasini and Badrinath R. Konety
As of 2012, bladder cancer is the fourth most common cancer afflicting men and
ninth most common cancer in women. Nearly 80% of all bladder cancer diagnoses
are non-muscle invasive at presentation, most of whom will develop recurrent dis-
ease within 5 years of initial diagnosis. Urinary tumor markers provide a noninvasive
method for both screening and surveillance of bladder cancer. This article reviews
the current Food and Drug Administration-approved urinary biomarkers for detec-
tion of non-muscle invasive bladder cancer.
Office-based Bladder Tumor Fulguration and Surveillance: Indications and Techniques 175
Brock B. O Neil and William T. Lowrance
This article summarizes the current literature on office-based management of low-
grade, noninvasive bladder cancer. Discussion includes differences in recurrence
and progression rates between neoplasm grades and stages, role of visual grading
for diagnosis, cost advantages of treatment outside the operating room, and a step-
by-step description of office-based procedures.
Perioperative Chemotherapy: When to Use It, What to Use, and Why 183
David C. Johnson, Raj S. Pruthi, and Michael E. Woods
This article provides an overview of intravesical chemotherapy agents used for
non-muscle invasive bladder cancer; summarizes the evidence on single-dose
Their Clinical Utility Be Improved?
155
vi
Contents
perioperative administration, induction therapy, and maintenance therapy; and
briefly discusses ongoing research.
Side Effects of Perioperative Intravesical Treatment and Treatment Strategies for
These Side Effects 197
Joshua G. Griffin and Jeff Holzbeierlein
Perioperative intravesical chemotherapy has a well-established role in the treatment
of non-muscle invasive bladder cancer. There are multiple agents that can be used
in this fashion with varying properties. Although chemical cystitis is the most com-
mon side effect and is usually self-limiting, significant toxicity can occur with intra-
vesical chemotherapy. It is imperative that the urologist is aware of the acute and
delayed side effects of intravesical chemotherapy and how to manage potential
complications. Both local and systemic toxicities are discussed, as well as strate-
gies to minimize and manage them.
Strategies for Optimizing Bacillus Calmette-Guérin 211
Jay B. Shah and Ashish M. Kamat
For treating patients with superficial bladder cancer and a moderate-to-high risk of
tumor recurrence or progression, intravesical BCG has been the key development of
the last generation. However, BCG has also brought with it a novel set of challenges.
An understanding of when, to whom, and how BCG should be given is critical if
optimal outcomes are to be achieved. This article the authors reviews the role that
BCG has played in the management of bladder cancer over the last several decades
and discusses specific approaches to optimize BCG. It focuses on selection and
technical strategies.
New Agents for Bacillus Calmette-Guérin-Refractory Bladder Cancer 219
Jennifer J. Ahn and James M. McKiernan
Bacillus Calmette-Guérin has been established as the primary treatment of high-risk
non-muscle invasive bladder cancer. If patients do not respond or later recur, the
most reliable treatment option is cystectomy. For those who are unwilling or unable
to undergo this significant procedure, there is a multitude of alternative intravesical
therapies. This article provides an overview of treatment options for patients with
non-muscle invasive bladder cancer who have failed intravesical bacillus Calmette-
Guérin therapy. It includes information on recent and ongoing trials and serves as
a guide for clinicians regarding available therapies and a reference for researchers
in this field.
Determining the Role of Cystectomy for High-grade T1 Urothelial Carcinoma 233
Siamak Daneshmand
High-grade T1 (HGT1) urothelial carcinoma is an invasive disease with high predis-
position for recurrence and progression. The optimal treatment of HGT1 disease
remains controversial. Clinical HGT1 disease represents a heterogeneous group
of patients with variable clinical behavior. Radical cystectomy for HGT1 disease is
associated with excellent survival and offers the best opportunity for cure; however,
it has a potential cost of decrease in quality of life. This article summarizes features
associated with increased risk of progression and provides a framework for optimal
treatment strategy with a focus on the role of radical cystectomy for HGT1 disease.
Contents
The Conundrum of Prostatic Urethral Involvement
Johann P. Ingimarsson and John D. Seigne
The presence and depth of urothelial cancer involvement in the prostatic urethra can
significantly affect the management of a patient with non-muscle invasive bladder
cancer. This article presents an overview of the incidence, diagnosis, management,
and follow-up of urothelial cancer.
The Costs of Non-Muscle Invasive Bladder Cancer
Andrew C. James and John L. Gore
Bladder cancer is a common diagnosis, affecting 70,000 Americans each year. Be-
cause the diagnosis, management, and long-term follow-up of non-muscle invasive
bladder cancer requires advanced imaging and invasive testing, economic evalua-
tions have shown bladder cancer to be the costliest cancer to treat in the US on
a per capita basis. Adjunctive tests for surveillance have not obviated the need for
cystoscopy and cytology. Indirect costs to patients include loss of work, decreased
productivity, and diminished quality of life associated with diagnosis, treatment, and
surveillance. Improved value may be achieved with better compliance with evi-
dence-based practices for non-muscle invasive bladder cancer care.
New Imaging Techniques for Non-Muscle Invasive Bladder Cancer: Ready for Primetime
Joseph A. Gillespie and Michael A. O Donnell
Treatment of non-muscle invasive bladder cancer (NMBIC) requires direct visual
appreciation of the tumor. Transurethral resection that is dependent solely on white
light cystoscopy (WLC) often fails to accurately stage or completely resect NMIBC.
These deficiencies of WLC are significant contributors to the high rates of recurrence
and eventual progression to muscle invasive disease. This article looks at technolo-
gies that are being used in adjunct to WLC to augment the urologist s ability to iden-
tify, stage, and treat NMIBC.
Diagnostically Challenging Cases: What are Atypia and Dysplasia?
Joseph Sanfrancesco, J. Stephen Jones, and Donna E. Hansel
This article addresses the spectrum of atypia and dysplasia within the bladder
epithelium and the diagnostic categories developed to further classify challenging
lesions. In addition, the effects of inflammation, specific therapies, and instrumenta-
tion on the bladder mucosa as well as the associated difficulty in achieving the
appropriate diagnosis are also discussed.
Restaging Transurethral Resection for Non-Muscle Invasive Bladder Cancer: Who, Why,
When, and How?
Chad R. Ritch, Peter E. Clark, and Todd M. Morgan
The rate of clinical understaging in non-muscle invasive bladder cancer (NMIBC)
after an initial transurethral resection (TUR) is significant, particularly for high-grade
disease, and this has a major impact on prognosis. A repeat TUR, 2 to 6 weeks fol-
lowing the initial resection, is recommended in appropriately selected cases to avoid
diagnostic inaccuracy and improve treatment allocation. This article summarizes the
rationale and indications for performing a repeat TUR in NMIBC and also provides
information regarding patient selection and technique.
viii Contents
Optimal Risk-Adapted Surveillance Strategies for NMIBC, Including Upper Tract Imaging 305
Michael C. Large, Joshua A. Cohn, and Gary D. Steinberg
Non-muscle invasive bladder cancer (NMIBC) represents approximately 70% of all
incident cases of bladder cancer. The financial burden of NMIBC continues to in-
crease, underscoring the importance of efficient, evidence-based management of
this disease. Consensus guidelines differ on risk definition and in management rec-
ommendations. This article reviews the incidence and financial impact of NMIBC
and details the recommendations for diagnosis, treatment, and surveillance made
by the American Urological Association, International Consultation on Bladder
Cancer-European Association of Urology, and National Comprehensive Cancer Net-
work. Established and developing adjunctive laboratory and imaging tests directed
at diagnosis and management of NMIBC are also discussed.
Index
317
|
| any_adam_object | 1 |
| building | Verbundindex |
| bvnumber | BV041021457 |
| ctrlnum | (OCoLC)844112158 (DE-599)BVBBV041021457 |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01236nam a2200313 cb4500</leader><controlfield tag="001">BV041021457</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">130517s2013 ad|| |||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781455773459</subfield><subfield code="9">978-1-4557-7345-9</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">145577345X</subfield><subfield code="9">1-4557-7345-X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)844112158</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV041021457</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-19</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Diagnosis, evaluation, and treatment of non-muscle invasive bladder cancer</subfield><subfield code="c">ed. Sam S. Chang</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Philadelphia, Pa.</subfield><subfield code="b">Elsevier</subfield><subfield code="c">2013</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XIII S., S. 155 - 321</subfield><subfield code="b">Ill., graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Urologic clinics of North America</subfield><subfield code="v">40,2</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Clinics review articles</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chang, Sam S.</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Urologic clinics of North America</subfield><subfield code="v">40,2</subfield><subfield code="w">(DE-604)BV000001584</subfield><subfield code="9">40,2</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">HBZ Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=025999024&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-025999024</subfield></datafield></record></collection> |
| id | DE-604.BV041021457 |
| illustrated | Illustrated |
| indexdate | 2024-07-10T00:37:12Z |
| institution | BVB |
| isbn | 9781455773459 145577345X |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-025999024 |
| oclc_num | 844112158 |
| open_access_boolean | |
| owner | DE-19 DE-BY-UBM |
| owner_facet | DE-19 DE-BY-UBM |
| physical | XIII S., S. 155 - 321 Ill., graph. Darst. |
| publishDate | 2013 |
| publishDateSearch | 2013 |
| publishDateSort | 2013 |
| publisher | Elsevier |
| record_format | marc |
| series | Urologic clinics of North America |
| series2 | Urologic clinics of North America Clinics review articles |
| spelling | Diagnosis, evaluation, and treatment of non-muscle invasive bladder cancer ed. Sam S. Chang Philadelphia, Pa. Elsevier 2013 XIII S., S. 155 - 321 Ill., graph. Darst. txt rdacontent n rdamedia nc rdacarrier Urologic clinics of North America 40,2 Clinics review articles Chang, Sam S. Sonstige oth Urologic clinics of North America 40,2 (DE-604)BV000001584 40,2 HBZ Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=025999024&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Diagnosis, evaluation, and treatment of non-muscle invasive bladder cancer Urologic clinics of North America |
| title | Diagnosis, evaluation, and treatment of non-muscle invasive bladder cancer |
| title_auth | Diagnosis, evaluation, and treatment of non-muscle invasive bladder cancer |
| title_exact_search | Diagnosis, evaluation, and treatment of non-muscle invasive bladder cancer |
| title_full | Diagnosis, evaluation, and treatment of non-muscle invasive bladder cancer ed. Sam S. Chang |
| title_fullStr | Diagnosis, evaluation, and treatment of non-muscle invasive bladder cancer ed. Sam S. Chang |
| title_full_unstemmed | Diagnosis, evaluation, and treatment of non-muscle invasive bladder cancer ed. Sam S. Chang |
| title_short | Diagnosis, evaluation, and treatment of non-muscle invasive bladder cancer |
| title_sort | diagnosis evaluation and treatment of non muscle invasive bladder cancer |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=025999024&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| volume_link | (DE-604)BV000001584 |
| work_keys_str_mv | AT changsams diagnosisevaluationandtreatmentofnonmuscleinvasivebladdercancer |